OBSAH

EDITORIAL

Miloslav Kopeček ............................................................................................................ 1

OBSAH............................................................................................................................. 3

PŮVODNÍ PRÁCE

Veronika Boleková, Filip Foriš
Typológia ľudí závislých od alkoholu z hľadiska ich kognitívnych výkonov ...................... 5

PŘEHLEDNÉ ČLÁNKY

Jiří Patočka, Zdeňka Navrátilová, Patrik Olekšák
Trehalóza – disacharid s neuroprotektivním účinkem ...................................................... 11

KAZUISTIKY

Miloslav Kopeček, Veronika Andrashko, Jiří Renka
Průlomová a udržovací léčba rezistentní depresivní
poruchy racemickým ketaminem – kazuistická studie ...................................................... 16

VZDĚLÁVÁNÍ

Klára Látalová
Základní farmakologická léčba generalizované úzkostné poruchy ................................... 20

FÓRUM ČESKÉ NEUROPSYCHOFARMAKOLOGICKÉ SPOLEČNOSTI

Martin Hýža, Petr Šilhán, David Škrda, Jan Vober, Jan Uhlíř,
Petr Dostálek, Tomáš Skřont, Samuel Ambroš, Eva Češková
Terapeutické monitorování psychofarmak 3:
využití u jednotlivých lékových skupin............................................................................... 27

ZPRÁVY

Petra Horáková 
67. česko-slovenská psychofarmakologická konference,
10.–14. 1. 2024, Mariánské Lázně.................................................................................... 37

DOPISY, OHLASY, DISKUZE

Miloslav Kopeček
`Pilotní studie škály PHQ-9 u studentů 5. ročníku 3. lékařské fakulty
Univerzity Karlovy v Praze................................................................................................ 39

Karel Nešpor
Účinky tělesné aktivity na psychiku................................................................................... 42

Václav Filip
Psychedelika u deprese a vizionář Ladislav Haškovec.................................................... 43

PŘEDPLATNÉ.............................................................................................................44 

CONTENTS

EDITORIAL

Miloslav Kopeček ............................................................................................................ 1

CONTENTS..................................................................................................................... 3

ORIGINAL PAPERS

Veronika Boleková, Filip Foriš
Cognitive performance-based typology of people with alcohol use disorders................... 5

REVIEWS

Jiří Patočka, Zdeňka Navrátilová, Patrik Olekšák
Trehalose – disaccharide with a neuroprotective effect .................................................. 11

CASE REPORTS

Miloslav Kopeček, Veronika Andrashko, Jiří Renka
Breakthrough and maintenance treatment of resistant
depressive disorder by racemic ketamine – a case study................................................ 16

CME

Klára Látalová
Basic pharmacological treatment of generalized anxiety disorder ................................... 20

FORUM OF THE CZECH NEUROPSYCHOPHARMACOLOGICAL SOCIETY

Martin Hýža, Petr Šilhán, David Škrda, Jan Vober, Jan Uhlíř,
Petr Dostálek, Tomáš Skřont, Samuel Ambroš, Eva Češková
Therapeutic monitoring of psychopharmaceuticals 3:
use for individual drug groups........................................................................................... 27

NEWS

Petra Horáková
67. Czech-Slovak Psychopharmacological Conference,
10.–14. 1. 2024, Mariánské Lázně.................................................................................... 37

CORRESPONDENCE

Miloslav Kopeček
Pilot study of the PHQ-9 scale in 5th year students of the 3rd Medical
Faculty of Charles University in Prague........................................................................... 39

Karel Nešpor
Effects of physical activity on the psyche.......................................................................... 42

Václav Filip
Psychedelics in depression and the visionary Ladislav Haškovec................................... 43

SUBSCRIPTION......................................................................................................... 44

Psychiatrie supplementum 1/2024

EDITORIAL .............................................................................................................. 1

OBSAH .................................................................................................................... 2

PROGRAM .............................................................................................................. 4

ODBORNÁ SYMPOZIA ........................................................................................... 9
Psychotická deprese ................................................................................................ 9
Zánět a psychotické poruchy: 2. část ..................................................................... 10
Sympózium Psychofarmakologickej sekcie SPsS SLS .......................................... 11
Současné trendy neurostimulace v klinické praxi ................................................... 12
Farmakoterapie a psychoterapie: spolu, nebo zvlášť? ........................................... 14
Obtížně léčebně ovlivnitelné příznaky schizofrenie ................................................ 14
Hříchy psychofarmakologické léčby ........................................................................ 15
Gama-6 a gama-3-mastné kyseliny – vývojová heterogenita –
odlišný biologický význam ....................................................................................... 15
Farmaka a poruchy příjmu potravy: Aktuální možnosti a problémy ......................... 16
Vojenská psychiatrie: Od válek v Jugoslávii do napadení Ukrajiny ......................... 18
Sympozium Společnosti pro biologickou psychiatrii:
Neuropsychiatrické poruchy a jejich léčba ............................................................... 18
Konspirační teorie v lékařské praxi .......................................................................... 20
Jak se vyhnout pastem psychofarmakoterapie: nebezpečí, limity a možnosti ......... 20
Léčba závislostí ........................................................................................................ 21
Sympozium PS ČLS JEP: Konopné drogy regulovat, či neregulovat? ..................... 22
Závislosti v gerontopsychiatrii ................................................................................... 23
Psychedelika, problémové děti psychofarmakologie IV ............................................ 24

NOVÝ VÝZKUM ........................................................................................................ 26
Pilíře klinické predikce antidepresivního efektu ketaminu ......................................... 26
Úloha přední cingulární kůry v inhibiční kontrole –
studie ACDC TMS u pacientů s obsedantně-kompulzivní poruchou ......................... 26
Fenokonverze metabolizmu olanzapinu kouřením .................................................... 27
Dopad léčby předčasné ejakulace na sexuální život žen .......................................... 27
Psychopatologie a kvalita života u onemocnění schizofrenního spektra:
katamnéza po 5 letech .............................................................................................. 27

VÝVĚSKOVÁ SDĚLENÍ ........................................................................................... 28
Preklinická P1–P11 .................................................................................................. 28
Klinická K1–K12 ....................................................................................................... 33

WORKSHOPY .......................................................................................................... 37
Psychiatrický drift: Slepé uličky v životě psychiatra .................................................. 37
Závislosti v praxi: 4 pilíře účinné farmakoterapie ...................................................... 37
Tajemství nevědomí: Thanatos a psychopatologie ................................................... 37
Různé cesty podání ketaminu v ambulaci i během hospitalizace ............................. 38

REJSTŘÍK ................................................................................................................. 39

POKYNY AUTORŮM ................................................................................................. 40

EDITORIAL .................................................................................................................. 1

CONTENTS ................................................................................................................. 2

PROGRAMME ............................................................................................................. 4

SCIENTIFIC SYMPOSIA ............................................................................................. 9
Psychotic depression ................................................................................................... 9
Inflammation and psychotic disorders: part 2 ............................................................. 10
Symposium of the Psychopharmacological section
of the Slovak Psychiatric Society ................................................................................ 11
Current trends of neurostimulation in clinical practice ................................................ 12
Pharmacotherapy and psychotherapy: together or separately? ................................. 14
Schizophrenia symptoms that are difficult to treat ...................................................... 14
Sins of psychopharmacological treatment .................................................................. 15
Gamma-6 and gamma-3-fatty acids – developmental heterogeneity –
different biological significance ................................................................................... 15
Pharmacology and eating disorders: Current options and issues ............................... 16
Military psychiatry: From the wars in Yugoslavia to the invasion of Ukraine ............... 18
Symposium of the Society for Biological Psychiatry (SBP) –
Neuropsychiatric disorders and their treatment ........................................................... 18
Conspiracy theories in medical practice ....................................................................... 20
Avoiding the pitfalls of psychopharmacotherapy:
dangers, limits and possibilities .................................................................................... 20
Treatment of addictions ................................................................................................ 21
Symposium of Czech Psychiatric Association:
To regulate or not to regulate cannabis drugs? ............................................................ 22
Addictions in gerontopsychiatry .................................................................................... 23
Psychedelics, problem children of psychopharmacology IV ......................................... 24

NEW RESEARCH ......................................................................................................... 26
Key clinical predictors of the antidepressant effect of ketamine .................................... 26
The role of the anterior cingulate cortex in inhibitory control –
the ACDC TMS study with patients with obsessive-compulsive disorder ...................... 26
Phenoconversion of olanzapine metabolism by smoking .............................................. 27
Impact of treatment of premature ejaculation on the sexual functions of women .......... 27
Psychopathology and quality of life in schizophrenia spectrum disorders:
five-year follow-up .......................................................................................................... 27

POSTERS ...................................................................................................................... 28
Preclinical P1–P11 ......................................................................................................... 28
Clinical K1–K12 .............................................................................................................. 33

WORKSHOPS ................................................................................................................ 37
Psychiatric drift: Blind alleys in the life of a psychiatrist .................................................. 37
Addictions in practice: 4 pillars of effective pharmacotherapy ........................................ 37
Secrets of the unconscious: Thanatos and psychopathology ......................................... 37
Different routes of ketamine administration in ambulatory
care and during hospitalization ....................................................................................... 38

INDEX ............................................................................................................................. 39

INSTRUCTION FOR AUTHORS .................................................................................... 40